NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, has announced that its 2025 Annual Shareholders Meeting will take place at 10 a.m. on Saturday, Nov. 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut. The announcement provides shareholders with the opportunity to engage with management and receive updates on the company's progress.
The meeting comes at a pivotal time for NanoViricides as it advances its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox. The company is currently focused on moving NV-387 into Phase II human clinical trials, a critical step toward potential regulatory approval.
In addition to NV-387, NanoViricides is developing NV-HHV-1 for the treatment of shingles and has a pipeline targeting numerous viral diseases, including oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola. The company's technology is based on the TheraCour nanomedicine platform, licensed from TheraCour Pharma, Inc., which enables the creation of special purpose nanomaterials for antiviral therapy.
Investors can find the latest news and updates regarding NNVC in the company's newsroom at https://ibn.fm/NNVC. The full press release about the shareholders meeting is available at https://ibn.fm/7IcXQ.
NanoViricides’ business model relies on licensing technology from TheraCour for specific viral applications, a strategy established at its founding in 2005. The company holds exclusive, sub-licensable field licenses for several drugs targeting human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses. It also intends to obtain licenses for RSV, poxviruses, and enteroviruses pending successful research.
However, the company cautions that drug development is an extremely lengthy process requiring substantial capital. There is no assurance that any of its drug candidates will demonstrate sufficient effectiveness and safety for human clinical development or that successful lab results will translate into successful clinical trials or commercial products. The path to regulatory approval is uncertain, and investors should consider these risks.
